Matisyahu Shulman, Miranda G Greiner, Hiwot M Tafessu, Onumara Opara, Kaitlyn Ohrtman, Kenzie Potter, Kathryn Hefner, Eve Jelstrom, Richard N Rosenthal, Kevin Wenzel, Marc Fishman, John Rotrosen, Udi E Ghitza, Edward V Nunes, Adam Bisaga
IMPORTANCE: Injectable extended-release (XR)-naltrexone is an effective treatment option for opioid use disorder (OUD), but the need to withdraw patients from opioid treatment prior to initiation is a barrier to implementation. OBJECTIVE: To compare the effectiveness of the standard procedure (SP) with the rapid procedure (RP) for XR-naltrexone initiation. DESIGN, SETTING, AND PARTICIPANTS: The Surmounting Withdrawal to Initiate Fast Treatment with Naltrexone study was an optimized stepped-wedge cluster randomized trial conducted at 6 community-based inpatient addiction treatment units...
May 1, 2024: JAMA Network Open